Peptides Research Hub

Clinical Trial Identifier

NCT03574597

Semaglutide 2.4 mg subcutaneous, part of the SELECT program.

Trial details

Identifier
NCT03574597
Sponsor
Novo Nordisk
Asset
Semaglutide 2.4 mg subcutaneous
Program
SELECT
Phase
Phase III
Therapeutic area
Cardiovascular

Program context

SELECT

20% relative reduction in the primary composite MACE endpoint (CV death, non-fatal MI, non-fatal stroke) with semaglutide 2.4 mg versus placebo over a median follow-up of approximately 40 months in adults with overweight/obesity and established CVD without diabetes.

Read the SELECT spotlight

Trial-level analysis lives in the program spotlight linked above. For the canonical registry record, including study design, eligibility, locations, and posted results, visit ClinicalTrials.gov.